Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis

Eugene P. Toy, Nathalie Bonafé, Asim Savlu, Caroline Zeiss, Wenxin Zheng, Maryann Flick, Setsuko K. Chambers

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Although proto-oncogene expression has been shown to correlate with clinical outcome in breast carcinoma, an experimental model has not been proposed to study this phenomenon in vivo. In addition, the ability to modulate this proto-oncogene in vivo to correlate with phenotypic behavior has not been determined. Utilizing an intraperitoneal model for metastatic spread with BT20 human breast carcinoma cells, clonally expanded cells expressing five fold higher c-fms protein were compared with parent BT20 cells as well as an underexpressing clone using intrasplenic injection following left flank cut-down in female nude and Severe combined immunodeficient (SCID) mice. Athymic BALB/c nude and SCID animals were observed for clinical evidence of tumorigenicity with necropsy performed at either 50 or 80 days unless compromised earlier. Immunohistochemistry (IHC) of the harvested tumors was performed to correlate c-fms expression from its original in vitro culture to the in vivo model. At day 50, differences in primary tumor take and spread to the pelvis were already evident favoring the c-fms over-expression group with IHC of these tumors revealing significantly higher intensity of staining for c-fms, (mean H score of 205 vs. 43 in the over-expression and parent groups, respectively). At day 80, tumor take and spread was comparable; however, tumor size in the over-expression group was significantly larger than the parent and under-expressing group in both the BALB/c and SCID experiments. Modulation of c-fms proto-oncogene expression was also achieved using the anti-glucocorticoid, RU-486, via oral administration to SCID mice with subsequent correlation to IHC staining. This model thus provides tumors of significant size and organ diversity which retain their phenotype early in tumorigenesis allowing an early endpoint to assess efficacy of novel treatments.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalClinical and Experimental Metastasis
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

fms Genes
Theoretical Models
Breast Neoplasms
Neoplasm Metastasis
Phenotype
Neoplasms
SCID Mice
Proto-Oncogenes
Immunohistochemistry
Macrophage Colony-Stimulating Factor Receptors
Staining and Labeling
Mifepristone
Aptitude
Organ Size
Pelvis
Glucocorticoids
Oral Administration
Carcinogenesis
Clone Cells
Injections

Keywords

  • Breast carcinoma
  • Experimental metastasis
  • Proto-oncogene

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. / Toy, Eugene P.; Bonafé, Nathalie; Savlu, Asim; Zeiss, Caroline; Zheng, Wenxin; Flick, Maryann; Chambers, Setsuko K.

In: Clinical and Experimental Metastasis, Vol. 22, No. 1, 01.01.2005, p. 1-9.

Research output: Contribution to journalArticle

Toy, Eugene P. ; Bonafé, Nathalie ; Savlu, Asim ; Zeiss, Caroline ; Zheng, Wenxin ; Flick, Maryann ; Chambers, Setsuko K. / Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. In: Clinical and Experimental Metastasis. 2005 ; Vol. 22, No. 1. pp. 1-9.
@article{9e74f7f487fc4bf39f57eaf27ccbdf0c,
title = "Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis",
abstract = "Although proto-oncogene expression has been shown to correlate with clinical outcome in breast carcinoma, an experimental model has not been proposed to study this phenomenon in vivo. In addition, the ability to modulate this proto-oncogene in vivo to correlate with phenotypic behavior has not been determined. Utilizing an intraperitoneal model for metastatic spread with BT20 human breast carcinoma cells, clonally expanded cells expressing five fold higher c-fms protein were compared with parent BT20 cells as well as an underexpressing clone using intrasplenic injection following left flank cut-down in female nude and Severe combined immunodeficient (SCID) mice. Athymic BALB/c nude and SCID animals were observed for clinical evidence of tumorigenicity with necropsy performed at either 50 or 80 days unless compromised earlier. Immunohistochemistry (IHC) of the harvested tumors was performed to correlate c-fms expression from its original in vitro culture to the in vivo model. At day 50, differences in primary tumor take and spread to the pelvis were already evident favoring the c-fms over-expression group with IHC of these tumors revealing significantly higher intensity of staining for c-fms, (mean H score of 205 vs. 43 in the over-expression and parent groups, respectively). At day 80, tumor take and spread was comparable; however, tumor size in the over-expression group was significantly larger than the parent and under-expressing group in both the BALB/c and SCID experiments. Modulation of c-fms proto-oncogene expression was also achieved using the anti-glucocorticoid, RU-486, via oral administration to SCID mice with subsequent correlation to IHC staining. This model thus provides tumors of significant size and organ diversity which retain their phenotype early in tumorigenesis allowing an early endpoint to assess efficacy of novel treatments.",
keywords = "Breast carcinoma, Experimental metastasis, Proto-oncogene",
author = "Toy, {Eugene P.} and Nathalie Bonaf{\'e} and Asim Savlu and Caroline Zeiss and Wenxin Zheng and Maryann Flick and Chambers, {Setsuko K.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s10585-005-0718-4",
language = "English (US)",
volume = "22",
pages = "1--9",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis

AU - Toy, Eugene P.

AU - Bonafé, Nathalie

AU - Savlu, Asim

AU - Zeiss, Caroline

AU - Zheng, Wenxin

AU - Flick, Maryann

AU - Chambers, Setsuko K.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Although proto-oncogene expression has been shown to correlate with clinical outcome in breast carcinoma, an experimental model has not been proposed to study this phenomenon in vivo. In addition, the ability to modulate this proto-oncogene in vivo to correlate with phenotypic behavior has not been determined. Utilizing an intraperitoneal model for metastatic spread with BT20 human breast carcinoma cells, clonally expanded cells expressing five fold higher c-fms protein were compared with parent BT20 cells as well as an underexpressing clone using intrasplenic injection following left flank cut-down in female nude and Severe combined immunodeficient (SCID) mice. Athymic BALB/c nude and SCID animals were observed for clinical evidence of tumorigenicity with necropsy performed at either 50 or 80 days unless compromised earlier. Immunohistochemistry (IHC) of the harvested tumors was performed to correlate c-fms expression from its original in vitro culture to the in vivo model. At day 50, differences in primary tumor take and spread to the pelvis were already evident favoring the c-fms over-expression group with IHC of these tumors revealing significantly higher intensity of staining for c-fms, (mean H score of 205 vs. 43 in the over-expression and parent groups, respectively). At day 80, tumor take and spread was comparable; however, tumor size in the over-expression group was significantly larger than the parent and under-expressing group in both the BALB/c and SCID experiments. Modulation of c-fms proto-oncogene expression was also achieved using the anti-glucocorticoid, RU-486, via oral administration to SCID mice with subsequent correlation to IHC staining. This model thus provides tumors of significant size and organ diversity which retain their phenotype early in tumorigenesis allowing an early endpoint to assess efficacy of novel treatments.

AB - Although proto-oncogene expression has been shown to correlate with clinical outcome in breast carcinoma, an experimental model has not been proposed to study this phenomenon in vivo. In addition, the ability to modulate this proto-oncogene in vivo to correlate with phenotypic behavior has not been determined. Utilizing an intraperitoneal model for metastatic spread with BT20 human breast carcinoma cells, clonally expanded cells expressing five fold higher c-fms protein were compared with parent BT20 cells as well as an underexpressing clone using intrasplenic injection following left flank cut-down in female nude and Severe combined immunodeficient (SCID) mice. Athymic BALB/c nude and SCID animals were observed for clinical evidence of tumorigenicity with necropsy performed at either 50 or 80 days unless compromised earlier. Immunohistochemistry (IHC) of the harvested tumors was performed to correlate c-fms expression from its original in vitro culture to the in vivo model. At day 50, differences in primary tumor take and spread to the pelvis were already evident favoring the c-fms over-expression group with IHC of these tumors revealing significantly higher intensity of staining for c-fms, (mean H score of 205 vs. 43 in the over-expression and parent groups, respectively). At day 80, tumor take and spread was comparable; however, tumor size in the over-expression group was significantly larger than the parent and under-expressing group in both the BALB/c and SCID experiments. Modulation of c-fms proto-oncogene expression was also achieved using the anti-glucocorticoid, RU-486, via oral administration to SCID mice with subsequent correlation to IHC staining. This model thus provides tumors of significant size and organ diversity which retain their phenotype early in tumorigenesis allowing an early endpoint to assess efficacy of novel treatments.

KW - Breast carcinoma

KW - Experimental metastasis

KW - Proto-oncogene

UR - http://www.scopus.com/inward/record.url?scp=23944479120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944479120&partnerID=8YFLogxK

U2 - 10.1007/s10585-005-0718-4

DO - 10.1007/s10585-005-0718-4

M3 - Article

VL - 22

SP - 1

EP - 9

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 1

ER -